Table 2.
Incremental cost-effectiveness analysis: per 1000 treated population.
| Total |
Incremental (compared with no intervention) |
ICER (compared with next best alternative) |
||||
|---|---|---|---|---|---|---|
| Cost (GH¢) | DALYs | Cost (GH¢) | DALYs avoided | ICER (GH¢ per DALY avoided) | ||
| NI | 536 562 | 13 447 | — | — | — | |
| TZD | 827 495 | 12 394 | 290 933 | 1052 | 276 | vs NI |
| CCB | 6 034 688 | 1523 | 5 498 126 | 1523 | 11 061 | vs TZD |
| ACEi | 5 383 737 | 690 | 4 847 175 | 690 | Dominated | |
| ARB | 3 934 709 | 416 | 3 398 147 | 416 | Dominated | |
| BB | 1 871 136 | 202 | 1 334 573 | 202 | Dominated | |
ACEi indicates angiotension converting enzyme inhibitor; ARB, angiotension receptor blocker; BB, beta-blockers; CCB, calcium channel blockers; DALYs, disability-adjusted life-years; GH¢, Ghana cedis; ICER, incremental cost-effectiveness ratio; NI, no intervention; TZD, thiazide-like diuretics.